Mindfulness-Based Cognitive Therapy for Depression and Anxiety
Launched by LADY DAVIS INSTITUTE · May 17, 2016
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients at least 60 years of age and above (clinical experience shows, that almost all patients with depressive and anxiety symptoms aged 60+ are able to participate in group MBCT)
- • Patients with depression and/or anxiety symptoms as indicated by scores of ≥10 on the Patient Health Questionnaire (PHQ-9) and/or General Anxiety Disorder-7 (GAD- 7)
- • Normal cognition or Mild Cognitive Impairment ("Normal" Result on the 3-minute Mini-Cog Test) \[28\]
- Exclusion Criteria:
- • Mild, Moderate, or Severe Dementia ("Abnormal" Result on the 3-minute Mini-Cog Test)
- • Acute psychotic symptoms
- • Severe personality problems that will interfere with their ability to function in a group setting
- • Acute Suicidal ideation/intent
- • Change in psychotropic medication during the 8 weeks of the intervention
- • Hearing impairment not improved with hearing aids and/or sound amplification
- • Unable to engage with MBCT for physical or practical reasons
- • Ongoing Active Psychotherapy
About Lady Davis Institute
The Lady Davis Institute (LDI) is a leading Canadian research organization dedicated to advancing health sciences through innovative clinical trials and translational research. Affiliated with the Jewish General Hospital in Montreal, LDI focuses on a multidisciplinary approach to understanding disease mechanisms and developing effective therapies. With a commitment to improving patient outcomes, the institute collaborates with academic institutions and industry partners to drive breakthroughs in areas such as cancer, cardiovascular health, and chronic diseases. Through its rigorous research programs and adherence to ethical standards, the Lady Davis Institute aims to contribute significantly to the global scientific community and enhance the quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials